R&DAstraZeneca2017-07-20 09:17Read 0
CHMP positive recommendation is based on Phase III data demonstrating a 20% reduction in risk of disease worsening or death over anastrozole
Commentsthelifesciencesreport2017-07-20 08:52Read 0
News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company.
TrendDKFZ2017-07-20 08:47Read 0
Medulloblastoma, a malignant tumour of the cerebellum, can occur at any age, but it most commonly affects children.
FrontierDana-Farber2017-07-20 08:42Read 0
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center -- using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice -- has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.
TrendScience 2017-07-20 08:39Read 0
Genetically modified "hunter" T cells successfully migrated to and penetrated a deadly type of brain tumour known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumour microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine.
R&DBlood2017-07-19 09:09Read 1
Researchers at the George Washington University (GW) Cancer Center have discovered a new role for the enzyme, histone deacetylase 11 (HDAC11), in the regulation of T-cell function.
R&DACS2017-07-19 09:06Read 1
Women with breast cancer who undergo nipple-sparing mastectomy (NSM) have a low rate of the cancer returning within the first five years, when most recurrences in the breast are diagnosed, findings of a single-centre study show.
EVENTSpmlive2017-07-19 09:03Read 1
Sales up 3% to $1.5bn in second quarter for ailing eyecare division
RegulatorEPvantage2017-07-19 09:00Read 1
Renewal of the US FDA’s user fee programme is must-pass legislation every five years, and usually becomes a vehicle for correcting weaknesses in the pharmaceutical sector. With drug prices the focus of industry critics, the 2017 version of this legislation seeks to constrain costs by stimulating generic competition.